pmid,title,journal,year,drug,disease
40733703,COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study.,Vaccines,2025,Ruxolitinib,COVID-19
40700055,Pharmacological Immunomodulation via Collagen-Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study.,Advances in respiratory medicine,2025,Ruxolitinib,COVID-19
40673198,Case Report: Intra-articular injection of tocilizumab for arthritis treatment in chronic graft-vs.-host disease.,Frontiers in pediatrics,2025,Ruxolitinib,COVID-19
40575972,Successful salvage therapy of ruxolitinib on interstitial pneumonia after long COVID or post-COVID-19 syndrome with follicular lymphoma: two case reports and literature review.,Chinese clinical oncology,2025,Ruxolitinib,COVID-19
40575645,COVID-19 management in patients with comorbid conditions.,World journal of virology,2025,Ruxolitinib,COVID-19
40488888,Wells syndrome: emerging triggers and treatments- an updated systematic review.,Archives of dermatological research,2025,Ruxolitinib,COVID-19
40430208,Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial.,"Life (Basel, Switzerland)",2025,Ruxolitinib,COVID-19
40378861,Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials.,The Lancet. Respiratory medicine,2025,Ruxolitinib,COVID-19
40372702,Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy.,"Rheumatology (Oxford, England)",2025,Ruxolitinib,COVID-19
40318419,Interference between SARS-CoV-2 and influenza B virus during coinfection is mediated by induction of specific interferon responses in the lung epithelium.,Virology,2025,Ruxolitinib,COVID-19
40197709,Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study.,The clinical respiratory journal,2025,Ruxolitinib,COVID-19
40100484,Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents.,Molecular diversity,2025,Ruxolitinib,COVID-19
40056149,"Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 - 2023).",Expert opinion on therapeutic patents,2025,Ruxolitinib,COVID-19
39937571,Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses.,The Journal of general virology,2025,Ruxolitinib,COVID-19
39828908,Interleukin 6 Is Significantly Increased in Severe Pneumonia After Allo-Hematopoietic Stem Cell Transplantation and Might Induce Lung Injury via IL-6/sIL-6R/JAK1/STAT3 Pathway.,The Journal of infectious diseases,2025,Ruxolitinib,COVID-19
39737903,Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages.,Nature communications,2024,Ruxolitinib,COVID-19
39214573,Cavitary lung lesions caused by Pneumocystis jirovecii in a patient with myelofibrosis on ruxolitinib.,BMJ case reports,2024,Ruxolitinib,COVID-19
39100065,Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report.,Cureus,2024,Ruxolitinib,COVID-19
38868321,Effect of JAK Inhibitors on the Risk of Death in Patients with Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.,The Canadian journal of hospital pharmacy,2024,Ruxolitinib,COVID-19
38838026,Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.,Leukemia & lymphoma,2024,Ruxolitinib,COVID-19
38568967,SARS-CoV-2 nsp15 endoribonuclease antagonizes dsRNA-induced antiviral signaling.,Proceedings of the National Academy of Sciences of the United States of America,2024,Ruxolitinib,COVID-19
38323709,Innate immune response to SARS-CoV-2 infection contributes to neuronal damage in human iPSC-derived peripheral neurons.,Journal of medical virology,2024,Ruxolitinib,COVID-19
38293201,JAK/STAT Signaling Predominates in Human and Murine Fungal Post-infectious Inflammatory Response Syndrome.,medRxiv : the preprint server for health sciences,2024,Ruxolitinib,COVID-19
38264533,Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system.,Frontiers in pharmacology,2023,Ruxolitinib,COVID-19
38014074,SARS-CoV-2 nsp15 endoribonuclease antagonizes dsRNA-induced antiviral signaling.,bioRxiv : the preprint server for biology,2023,Ruxolitinib,COVID-19
38013675,Solid organ graft-versus-host disease in a recipient of a COVID-19 positive liver graft.,Journal of liver transplantation,2023,Ruxolitinib,COVID-19
37984996,Increasing insight in the value of repetitive COVID-19 vaccination in patients with haematological malignancies in the Omicron era.,British journal of haematology,2024,Ruxolitinib,COVID-19
37902541,[Clinical trials approved by Aifa for Covid-19: report of the main results to fill the unmet medical need.].,Recenti progressi in medicina,2023,Ruxolitinib,COVID-19
37886583,Translating GWAS Findings to Inform Drug Repositioning Strategies for COVID-19 Treatment.,Research square,2023,Ruxolitinib,COVID-19
37811764,An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination.,Human vaccines & immunotherapeutics,2023,Ruxolitinib,COVID-19
37624300,"Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus.",Veterinary sciences,2023,Ruxolitinib,COVID-19
37568402,Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study.,Journal of clinical medicine,2023,Ruxolitinib,COVID-19
37528650,Structure and dynamics of whole-sequence homology model of ORF3a protein of SARS-CoV-2: An insight from microsecond molecular dynamics simulations.,Journal of biomolecular structure & dynamics,2024,Ruxolitinib,COVID-19
37508292,Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study.,"Antibiotics (Basel, Switzerland)",2023,Ruxolitinib,COVID-19
37507425,The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.,Leukemia,2023,Ruxolitinib,COVID-19
37497193,A case of T-cell-Epstein-Barr virus-haemophagocytic lymphohistiocytosis and sustained remission following ruxolitinib therapy.,Clinical & translational immunology,2023,Ruxolitinib,COVID-19
37329322,Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2.,Journal of chemical information and modeling,2023,Ruxolitinib,COVID-19
37293294,Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.,Frontiers in medicine,2023,Ruxolitinib,COVID-19
37269750,Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy.,Leukemia research,2023,Ruxolitinib,COVID-19
37189112,Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.,Cell communication and signaling : CCS,2023,Ruxolitinib,COVID-19
37143685,Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.,Frontiers in immunology,2023,Ruxolitinib,COVID-19
37137878,Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.,Blood cancer journal,2023,Ruxolitinib,COVID-19
37131454,Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report.,Infection and drug resistance,2023,Ruxolitinib,COVID-19
36923264,Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.,Therapeutic advances in hematology,2023,Ruxolitinib,COVID-19
36877872,Successful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy.,Journal of drugs in dermatology : JDD,2023,Ruxolitinib,COVID-19
36865808,Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.,Frontiers in oncology,2023,Ruxolitinib,COVID-19
36834974,Recognition of Differentially Expressed Molecular Signatures and Pathways Associated with COVID-19 Poor Prognosis in Glioblastoma Patients.,International journal of molecular sciences,2023,Ruxolitinib,COVID-19
36738826,JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.,Journal of thrombosis and haemostasis : JTH,2023,Ruxolitinib,COVID-19
36636972,"Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19).",Kardiologiia,2022,Ruxolitinib,COVID-19
36569952,Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections.,Frontiers in immunology,2022,Ruxolitinib,COVID-19
